Results 91 to 100 of about 790,800 (335)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

open access: yesMolecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan   +9 more
wiley   +1 more source

Race-specific leaf and root resistance of winter oilseed rape (Brassica napus L.) to Xanthomonas campestris pv. campestris

open access: yesSiberian Journal of Life Sciences and Agriculture
Background. Researchers from France, Serbia, and Russia have reported the spread of Black Rot in winter rape crop. The cultivation of resistant varieties and hybrids is considered to be the most effective method of reducing the economic damage caused by ...
Anastasiia V. Vishnyakova   +4 more
doaj   +1 more source

Marrying Out: One-in-Seven New U.S. Marriages Is Interracial or Interethnic [PDF]

open access: yes, 2010
Examines trends in and attitudes toward marriages between different races/ethnicities since 1980, including rates of intermarriage by race/ethnicity, gender, region, education, and age.
Jeffrey S. Passel   +2 more
core  

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

Phaseolin diversity in cultivated common bean from the Caribbean Diversidad de faseolinas en frijol común cultivado del Caribe

open access: yesActa Agronómica, 2007
<span style="font-size: 10pt; font-family: Verdana">In this study, 180 genotypes of cultivated <em>Phaseolus vulgaris </em>from the Caribbean were evaluated with the phaseolin marker.
Hidalgo Rigoberto   +2 more
doaj  

Close Rematches For NH Congressional Seats 10/24/2012 [PDF]

open access: yes, 2012
The races for both of New Hampshire’s congressional seats remain very close as Democrats Carol Shea-Porter and Anne McLane Kuster attempt to unseat their 2010 opponents, Republicans Frank Guinta and Charlie Bass.
Survey Center, UNH
core   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

Advantage, Incumbent [PDF]

open access: yes, 2008
Highlights findings on the advantage incumbents and those with fundraising success had in the 2002, 2004, and 2006 state legislative races, as well as the correlation between the two advantages.
Scott Jordan
core  

Home - About - Disclaimer - Privacy